A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Memorial Sloan Kettering Cancer Center (MSK)

Status: Withdrawn

Conditions: CLL/SLL; CLL; Small Lymphocytic Lymphoma; SLL; Chronic Lymphocytic Leukemia

Treatments: Other: Treatment Free Observation

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04694560

20-284

Details and patient eligibility

About

The purpose of this study is to find out whether people with CLL or SLL who are currently receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months, if they have achieved complete or partial remission of their disease.

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• ≥ 18-years-old

• Diagnosis of CLL or SLL confirmed by the enrolling institution

• Negative del(17p) test confirmed by FISH testing prior to initiating treatment with ibrutinib

• Receiving commercial treatment with an ibrutinib-based regimen in the front-line setting as defined below with the intent to discontinue therapy on C1D1:

  1. Ibrutinib monotherapy
  2. Ibrutinib in combination with anti-CD20 monoclonal antibody (Patients must have completed the anti-CD20 monoclonal antibody portion of the regimen prior to signing consent)

• Patients must have received ibrutinib-based therapy for at least 15 months. Dose interruptions and reductions during this treatment period may have been carried out per treating provider discretion.

• Response evaluation performed by radiology assessment (CT or MRI imaging of neck / chest / abdomen / pelvis) confirming complete remission or partial remission by iwCLL criteria.

• Peripheral blood (by flow cytometry per institutional standards) testing for MRD confirming U-MRD to a sensitivity of 10^-4. MRD testing must be confirmed to follow ERIC consensus criteria.

  1. CR with or without U-MRD in peripheral blood
  2. PR with U-MRD in peripheral blood

Exclusion criteria

• Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk..
• Unwilling or unable to participate in all required study evaluations and procedures. Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).

Trial design

0 participants in 1 patient group

CLL/SLL

Description:

Diagnosis of CLL or SLL confirmed by the enrolling institution

Treatment:

Other: Treatment Free Observation